• 1.The First Department of General Surgery, Affiliated No.3 People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201999, China;;
  • 2.Graduate School, Bengbu Medical College, Bengbu 233030, Anhui Province, China;
YU Jiwei., Email: jiweiyu919@hotmail.com
Export PDF Favorites Scan Get Citation

Objective  To summarize the development of gallbladder carcinoma related resistance genes and targeted therapy.
Methods  Domestic and international publications online involving resistance genes and targeted therapy of gallbladder carcinoma in recent years were collected and reviewed.
Results  Recent studies had shown that chemotherapy drug resistance of gallbladder carcinoma mainly involved lysosome protein transmembrane β4 (LAPTM4B) gene, NF-E2-related factor 2 (Nrf2) gene, and cancer stem cells (CSCs). While the latest gene targets of treatment for gallbladder carcinoma mainly involved LAPTM4B, Nemo-like kinase (NLK), tissue factor way inhibitor-2 (TFPI-2), vascular endothelial growth factor-D (VEGF-D), epidermal growth factor receptor (EGFR), and melanoma differentiation-associated gene 7/interleukin 24 (mda-7/IL-24) gene.
Conclusion  The research involving resistance genes and targeted therapy of gallbladder carcinoma has make a certain progress, which broaden the concept of traditional treatment of gallbladder carcinoma.

Citation: YU Yuanlin,JIANG Bojian,YU Jiwei.. Research Progress of Resistance Genes and Targeted Therapy for Gallbladder Carcinoma. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2013, 20(12): 1432-1436. doi: Copy